Research programme: tubulin polymerisation inhibitors - Onconova Therapeutics

Drug Profile

Research programme: tubulin polymerisation inhibitors - Onconova Therapeutics

Alternative Names: ON-015640; ON-24160

Latest Information Update: 22 Apr 2013

Price : $50

At a glance

  • Originator Onconova Therapeutics
  • Class Indoles; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 22 Apr 2013 Pharmacodynamics data presented at the 245th National Meeting of the American Chemical Society (ACS-2013)
  • 08 Sep 2010 Early research is ongoing in USA
  • 08 Sep 2010 Research programme: tubulin polymerisation inhibitors - Onconova Therapeutics is available for licensing. http://www.onconova.com/partneringopportunities.shtml
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top